All News

2057 articles, sorted by publication time.

Drug Development · global

AI-designed pulmonary fibrosis drug enters Phase III, moving efficacy testing to one year of follow-up

Rentosertib has entered a Phase III trial that will test early lung function signals in 320 patients over 52 weeks of treatment. In the same month, an AI drug discovery company spun off from ByteDance reportedly raised substantial funding. Capital and clinical development are advancing in parallel, but each addresses a different question of value.